Jesús García-Donas

TL;DR: The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.

TL;DR: Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliporib maintenance therapy led to significantly longer progression-free survival than carboplati plus pac Litaxel induction therapy alone.

TL;DR: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival and suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

TL;DR: Polymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability, and should promote interventional studies testing alternative therapeutic approaches for patients with such variants.

TL;DR: In each case, the allele causing increased pac litaxel metabolism was associated with increased neurotoxicity, suggesting an important role for metabolism and hydroxylated paclitaxel metabolites.